Clinical trial NCT02810171: Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety
Official title: Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety Disorders
Social Anxiety Disorder
Social Phobia
Generalized Anxiety Disorder
Separation Anxiety Disorder
Specific Phobia
Phobia
Agoraphobia
Panic Disorder
Panic Attack
Anxiety
Keywords: anxiety
social anxiety disorder
generalized anxiety disorder
phobias
fears
worry
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Ohio State University
name: National Institute of Mental Health (NIMH)
First posted: 2016-06-22
Enrollment: 207
Sex: ALL
Minimum age (years): 7
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Anxiety is among the most prevalent, costly and disabling illnesses and tends emerge early in childhood. Cognitive behavioral therapy (CBT) is the first-line treatment for early life anxiety, but as many as 40% of young patients who receive CBT fail to get better. The proposed study will examine brain changes marking positive response to CBT for anxiety and how these changes may differ in children compared adolescents. By helping us to understand how CBT works, this study will pave the way for new treatments to stop anxiety early.

Detailed description: Impairing anxiety affects 33% of the population by adolescence and can become chronic, leading to depression, substance abuse, school-drop out and even suicide. To reduce anxiety and prevent its sequelae, patients must be effectively treated early; yet, the first line intervention, cognitive behavioral therapy (CBT), has a heterogeneous response with 40-60% of treated patients continuing to experience impairment from residual symptoms. The reasons for variability in CBT outcomes remain poorly understood, but individual (including developmental) differences in brain-behavioral targets of CBT may contribute. This proposal addresses two primary questions: 1) Do individual differences in CBT-relevant brain-behavioral functions lead to variation in CBT outcomes? and 2) Does development contribute to this variation? To answer these questions, this study will measure changes in brain and behavior markers of anxiety, before and after CBT, in children and adolescents across traditional, categorical anxiety disorders (e.g., social, generalized and separation anxiety disorders). Given that CBT facilitates control over fear to enable effective regulation, the investigators hypothesize that brain-behavioral markers of fear sensitivity, cognitive regulatory capacity and cognitive regulation of fear will predict and characterize mechanisms of CBT effect. In addition, the investigators hypothesize that these markers will differentially relate to CBT effect, depending on patient age.

Children and adolescents (7.0 - 17.99 years) with clinically impairing anxiety will be randomized to receive CBT or a relaxation control therapy for 12 weeks. Before and after therapy, all participants will receive an MRI scan to see what regions of the brain become active when emotion and concentration tasks are performed and how that activation is changed after CBT.

While the study itself is of parallel design for its data-collection and measurement purpose, it is listed as a partial-crossover design in the IRB-approved protocol because subjects randomized to the relaxation therapy are given the option of receiving 12-weeks of CBT sessions after the relaxation therapy data has been collected. Some limited data will be collected in patients who are initially randomized to relaxation therapy but then opt to crossover to CBT. MRI data will also be collected in healthy youth before and after 12 weeks (but without intervening therapy) to allow the investigators to control for the simple effects of time that may cause brain changes that are not related to therapy.

Eligibility criteria: Inclusion Criteria for all participants (Clinically Anxious and Healthy):

* Age 7.0 - 17.99 years
* Parent or guardian able and willing to give informed consent
* Ability to tolerate small, enclosed spaces

Exclusion criteria for all participants (Clinically Anxious and Healthy)

* No metals, implants or metallic substances within or on the body (e.g., orthodontic braces)
* Vision equal to or better than 20/30 on a Snelling chart, with correction if necessary
* Not currently taking any psychotropic medication or receiving any psychotherapy (stable doses of stimulants allowable for anxiety subjects with comorbid attention deficit hyperactivity disorder) or receiving hormone therapy other than birth control
* No lifetime diagnoses of psychotic disorder, mental retardation or autism
* No history of current substance/alcohol abuse/dependence
* No evidence of suicidal intentions or behaviors in the past 6 months
* No history of serious medical or neurological illness
* If post-pubertal female, not pregnant

Additional Inclusion Criteria for Clinically Anxious Participants:

* Clinically significant anxiety as determined by structured clinical interview
* Past history of major depressive episodes are allowable
* Past history substance/alcohol abuse allowable if in remission for at least 1 year
* Obsessive-compulsive disorder symptoms are acceptable if not the primary source of interference or distress
* Anxiety must be primary concern, still bothersome, and CBT for anxiety determined to be appropriate treatment

Additional exclusion criteria for Healthy Participants:

* No history of past or current mental illness as determined by structured clinical interview

Primary outcomes:
measure: Brain function/structure as assessed by Magnetic Resonance Imaging scans
timeFrame: Baseline and 12-weeks
Secondary outcomes:
measure: Pediatric Anxiety Rating Scale
timeFrame: weeks 0, 3, 6, 9, 12
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Kate D. Fitzgerald, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rueppel M, Mannella KA, Fitzgerald KD, Schroder HS. Post-error slowing in anxiety and obsessive-compulsive disorders. Cogn Affect Behav Neurosci. 2022 Jun;22(3):610-624. doi: 10.3758/s13415-021-00976-9. Epub 2021 Dec 29.